A cytotoxic T-lymphocyte clone derived from mice with progressively growing tumors
S. K. Hoover, T. H. Inge, J. L. Frank, G. McKinnon, J. Monaco, B. Susskind and H. D. Bear
Massey Cancer Center, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
Tumor-specific T-cell clones were derived from spleen cells of mice bearing
a syngeneic PHS-5 tumor (a P815 mastocytoma mutant). Cells were expanded in
vitro and characterized and assayed for activity against the relevant tumor
in vivo. Clone cells were CD4-, CD8+ T lymphocytes, as determined by
fluorescence activated cell sorting analysis and were specifically
cytotoxic against P815 tumor cells in vitro, as shown in chromium 51
release assays. These cells require both antigen and interleukin 2 to
proliferate; neither alone is sufficient, even with the addition of
interleukin 1. In an experimental P815 liver metastasis model, the adoptive
transfer of GD11 or GD11.17 clone cells and injection of recombinant
interleukin 2 (7500 U intraperitoneally) 3 days after infusion of tumor
cells reduced the number of tumor nodules, while the adoptive transfer of
lymphokine-activated killer cells was ineffective.